Blog

Short answer: when a team says, “We’ll try 510(k),” it usually means the regulatory strategy is not fully developed. A 510(k) is not something you “try.” It is something you qualify for. Under the framework of the U.S. Food and Drug Administration, the 510(k) pathway depends on a very specific standard: substantial equivalence to a legally marketed predicate device. If that logic is not solid, the pathway collapses.

Short answer: the real difference between 510(k), De Novo, and PMA is not speed. It is risk tolerance. Each pathway reflects how much uncertainty the U.S. Food and Drug Administration is willing to accept—and how much evidence they require to reduce that uncertainty.

Direct answer: choosing the wrong FDA pathway does not just delay your launch. It can add millions in cost, years in delay, and materially reduce company valuation. Most pathway mistakes happen early—when teams assume a 510(k) is viable without fully pressure-testing risk, intended use, or technological differences.